סך נכסי הפעילות העסקית Axsome (AXSM)

Axsome Therapeutics (AXSM) is demonstrating steady sales growth for its migraine and depression treatments, maintaining independence from macroeconomic cycles. The success of Auvelity and the expansion of therapeutic areas are creating positive momentum. The company's aggregate resources on the chart confirm financial strength, where 700.69 determines the current value of the metric. Operations are complemented by strict adherence to environmental standards and a responsible approach to industrial waste disposal.

Total assets represent the sum of all company resources, reverse-calculated via ROA to eliminate information gaps between quarterly reports. By analyzing fluctuations in total assets, an investor assesses capital management efficiency, which is critically important for Axsome Therapeutics (AXSM) when scaling sales of patented drugs for the therapy of depressive disorders and expanding its commercial presence in the CNS market.